Search

Search Results

1. Novel therapies for growth disorders

   As we continue to understand more about the complex mechanism of growth, a plethora of novel therapies have recently been developed that aim to...

   Despoina M. Galetaki, Nadia Merchant, Andrew Dauber in European Journal of Pediatrics

   Article 13 October 2023

2. Advances in neonatal cell therapies: Proceedings of the First Neonatal Cell Therapies Symposium (2022)

   Abstract

   Despite considerable advances, there is a need to improve the outcomes of newborn infants, especially related to prematurity, encephalopathy...

   Atul Malhotra, Bernard Thebaud, ... Courtney A. McDonald in Pediatric Research

   Article Open access 28 June 2023
   

3. Cell-based therapies for neurological disorders — the bioreactor hypothesis

   Cell-based therapies are an emerging biopharmaceutical paradigm under investigation for the treatment of a range of neurological disorders....

   Sean I. Savitz, Charles S. Cox Jr in Nature Reviews Neurology

   Article 17 November 2022
   

4. A target map of clinical combination therapies in oncology: an analysis of clinicaltrials.gov

   Combination therapies have taken center stage for cancer treatment, however, there is a lack of a comprehensive portrait to quantitatively map the...

   **g Yang, Heming Kang, ... Yuanjia Hu in Discover Oncology

   Article Open access 21 August 2023
   

5. Translating the ALS Genetic Revolution into Therapies: A Review

   Purpose of Review

   Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease causing weakness, respiratory failure, and death within 3 to...

   Christine Meadows, Naraharisetty Anita Rau, ... Cindy V. Ly in Current Treatment Options in Neurology

   Article 30 January 2024

6. Myasthenia gravis: the changing treatment landscape in the era of molecular therapies

   Myasthenia gravis (MG) is an autoimmune disorder that affects the neuromuscular junction, leading to muscle weakness and fatigue. MG is caused by...

   Raffaele Iorio in Nature Reviews Neurology

   Article 08 January 2024
   

7. Dental Adverse Effects of Anti-CD20 Therapies

   Introduction

   Over the past few years, anti-CD20 therapies like rituximab, ocrelizumab or ofatumumab have seen an increase in interest in the treatment...

   Hélène Bartak, Tasnim Fareh, ... Christine Lebrun-Frenay in Neurology and Therapy

   Article Open access 26 April 2024

8. Anti-amyloid Antibody Therapies for Alzheimer’s Disease

   Alzheimer’s disease (AD) is the most common cause of dementia, which is characterized by a progressive neurodegenerative disorder that is extremely...

   Kyung Won Park in Nuclear Medicine and Molecular Imaging

   Article 20 February 2024
   

9. Diabetes current and future translatable therapies

   Diabetes is one of the major diseases and concerns of public health systems that affects over 200 million patients worldwide. It is estimated that...

   Fabio Antonio Gonzalez-Sanchez, Triana Mayra Sanchez-Huerta, ... Rebeca Garcia-Varela in Endocrine

   Article 06 July 2024
   

10. Podocyte-targeted therapies — progress and future directions

    Podocytes are the key target cells for injury across the spectrum of primary and secondary proteinuric kidney disorders, which account for up to 90%...

    Kristin Meliambro, John C. He, Kirk N. Campbell in Nature Reviews Nephrology

    Article 09 May 2024
    

11. Alzheimer’s Disease: Combination Therapies and Clinical Trials for Combination Therapy Development

    Alzheimer’s disease (AD) is a complex multifaceted disease. Recently approved anti-amyloid monoclonal antibodies slow disease progression by...

    Jeffrey L. Cummings, Amanda M. Leisgang Osse, ... **gchun Chen in CNS Drugs

    Article Open access 27 June 2024
    

12. Beyond fluorescence-guided resection: 5-ALA-based glioblastoma therapies

    Glioblastoma is the most common primary malignant brain tumor. Despite advances in multimodal concepts over the last decades, prognosis remains poor....

    Walter Stummer, Michael Müther, Dorothee Spille in Acta Neurochirurgica

    Article Open access 02 April 2024
    

13. Evidence-Based Update on Transcatheter Therapies for Pulmonary Embolism

    Purpose of Review

    Pulmonary embolism (PE) remains a leading cause of cardiovascular morbidity and mortality. Multiple new therapies are in development...

    Peter Monteleone, Akash Patel, Jonathan Paul in Current Cardiology Reports

    Article 24 April 2024
    

14. Cholestatic Pruritus: Pathophysiology, Current Management Approach, and Emerging Therapies

    Purpose of Review

    Cholestatic pruritus refers to the sensation of itch experienced by patients with disease processes impairing bile flow. This...

    Vishwajit Kode, Kidist K. Yimam in Current Hepatology Reports

    Article Open access 26 February 2024
    

15. Novel epigenetic molecular therapies for imprinting disorders

    Genomic imprinting disorders are caused by the disruption of genomic imprinting processes leading to a deficit or increase of an active allele. Their...

    Sung Eun Wang, Yong-hui Jiang in Molecular Psychiatry

    Article Open access 25 August 2023
    

16. Injection-based Therapies for Knee Osteoarthritis: A Comprehensive Update

    Purpose of Review

    This review is designed to explore the evolving landscape of intra-articular injection therapies for knee osteoarthritis (OA).

    ...

    Zack Crockett, Ofure Asikhia, ... George Ross Malik in Current Physical Medicine and Rehabilitation Reports

    Article 29 June 2024
    

17. Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia

    Background

    The treatment landscape for chronic lymphocytic leukemia (CLL) continues to undergo considerable evolution. Optimal selection of initial...

    Rory Bennett, Mary Ann Anderson, John F. Seymour in Journal of Hematology & Oncology

    Article Open access 08 July 2023
    

18. Engineering approaches for RNA-based and cell-based osteoarthritis therapies

    Osteoarthritis (OA) is a chronic, debilitating disease that substantially impairs the quality of life of affected individuals. The underlying...

    Carlisle R. DeJulius, Bonnie L. Walton, ... Craig L. Duvall in Nature Reviews Rheumatology

    Article 22 January 2024
    

19. Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathy

    Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) is an underrecognized cause of heart failure due to misfolded wild-type transthyretin...

    Danni Wu, Wei Chen in Heart Failure Reviews

    Article Open access 18 January 2024
    

20. Tolerance-inducing therapies in coeliac disease — mechanisms, progress and future directions

    Coeliac disease is an autoinflammatory condition caused by immune reactions to cereal gluten proteins. Currently, the only available treatment for...

    Ludvig M. Sollid in Nature Reviews Gastroenterology & Hepatology

    Article 09 February 2024